Home » Stocks » OSMT

Osmotica Pharmaceuticals PLC (OSMT)

Stock Price: $5.37 USD -0.21 (-3.76%)
Updated Oct 28, 2020 12:07 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 342.52M
Revenue (ttm) 211.55M
Net Income (ttm) -155.43M
Shares Out 63.78M
EPS (ttm) -2.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $5.37
Previous Close $5.58
Change ($) -0.21
Change (%) -3.76%
Day's Open 5.47
Day's Range 5.15 - 5.47
Day's Volume 155,523
52-Week Range 2.81 - 9.67

More Stats

Market Cap 342.52M
Enterprise Value 474.59M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 63.78M
Float 15.64M
EPS (basic) -2.94
EPS (diluted) -2.81
FCF / Share 0.86
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 14.72%
Payout Ratio n/a
Shares Short 1.96M
Short Ratio 3.59
Short % of Float 12.50%
Beta 2.61
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 6.79
PS Ratio 1.62
PB Ratio 2.86
Revenue 211.55M
Operating Income -152.66M
Net Income -155.43M
Free Cash Flow 50.42M
Net Cash -132.08M
Net Cash / Share -2.07
Gross Margin 60.69%
Operating Margin -72.16%
Profit Margin -73.50%
FCF Margin 23.83%
ROA 1.01%
ROE -79.95%
ROIC -50.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (6)

Buy 5
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(76.91% upside)
Current: $5.37
Target: 9.50
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-8.98%7.31%12.49%-
Gross Profit12812412192.84
Operating Income-281-98.54-52.07-32.05
Net Income-271-110-41.14-41.82
Shares Outstanding52.3745.2842.861.00
Earnings Per Share-5.17-2.42-0.96-41.81
Operating Cash Flow33.5737.5657.84-44.79
Capital Expenditures-4.02-4.13-6.90-13.93
Free Cash Flow29.5533.4250.94-58.72
Cash & Equivalents95.8770.8334.7419.56
Total Debt273269321329
Net Cash / Debt-177-198-286-309
Book Value115384436465
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Osmotica Pharmaceuticals PLC
Country United States
Employees 379
CEO Brian A. Markison

Stock Information

Ticker Symbol OSMT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: OSMT


Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone, a chlorzoxazone scored tablet for muscle spasms; ConZip, a tramadol hydrochloride extended-release capsule to treat pain; and Arbaclofen tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity. It also provides women's health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorder and social anxiety disorder; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; and prescription prenatal vitamins for treating nutritional requirements during pregnancy, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.